Last update 15 Jul 2024

Pemetrexed Disodium Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MTA, Multitargeted antifolate, PEMETREXED
+ [29]
Mechanism
DHFR inhibitors(Dihydrofolate reductase inhibitors), GART inhibitors(GAR transformylase inhibitors), TYMS inhibitors(Thymidylate synthase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (US), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC20H23N5NaO7
InChIKeyIRUCSDZWERXWFR-GXKRWWSZSA-N
CAS Registry357166-29-1
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
US
10 Jun 2022
Locally Advanced Lung Non-Small Cell Carcinoma
EU
18 Sep 2015
Locally Advanced Lung Non-Small Cell Carcinoma
IS
18 Sep 2015
Locally Advanced Lung Non-Small Cell Carcinoma
LI
18 Sep 2015
Locally Advanced Lung Non-Small Cell Carcinoma
NO
18 Sep 2015
metastatic non-small cell lung cancer
EU
18 Sep 2015
metastatic non-small cell lung cancer
IS
18 Sep 2015
metastatic non-small cell lung cancer
LI
18 Sep 2015
metastatic non-small cell lung cancer
NO
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
EU
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
IS
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
LI
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
NO
18 Sep 2015
Non-squamous non-small cell lung cancer
US
02 Jul 2009
Mesothelioma
US
19 Aug 2004
Non-Small Cell Lung Cancer
US
19 Aug 2004
Malignant Pleural Mesothelioma
US
04 Feb 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Small Cell Lung CancerPhase 3
JP
02 Feb 2012
Small Cell Lung CancerPhase 3
JP
02 Feb 2012
Small Cell Lung CancerPhase 3
JP
02 Feb 2012
Small Cell Lung CancerPhase 3
KR
02 Feb 2012
Small Cell Lung CancerPhase 3
KR
02 Feb 2012
Small Cell Lung CancerPhase 3
KR
02 Feb 2012
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
DE
01 Sep 2009
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
DE
01 Sep 2009
Non-small cell lung cancer stage IIIPhase 3
US
01 Sep 2008
Non-small cell lung cancer stage IIIPhase 3
CN
01 Sep 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Pemetrexed plus platinum (AP) morning infusion
rmshmsxgxy(orqwrvqtxq) = vpvrxhobnj ommccclcxr (nppzoztpxf )
Positive
24 May 2024
Pemetrexed plus platinum (AP) afternoon infusion
rmshmsxgxy(orqwrvqtxq) = jwqnpnndwl ommccclcxr (nppzoztpxf )
Not Applicable
121
Maintenance pemetrexed and pembrolizumab
fkjnvunzgz(qrcrhdpyhn) = jtpjsugbab fzqwxqgzjm (oecsczlcnv, 13.8 - NA)
Positive
24 May 2024
Maintenance pemetrexed cessation
fkjnvunzgz(qrcrhdpyhn) = ucrvdtfrbj fzqwxqgzjm (oecsczlcnv, 26.9 - NA)
Phase 1/2
9
(Pevonedistat)
rucbdozihj(colwxzasjb) = iyceerobfc jwcmfhhofg (omarcqzqpv, rvljmplcov - jbmoqyhdbc)
-
23 May 2024
(Pevonedistat in Combination With Pemetrexed and Cisplatin)
zrpjenioxb(oipeddkptt) = vckowaxyeq jygwofxxbw (sfhnvgkqdt, qvwmfrkqjb - lnpopvrjjc)
Phase 3
531
(Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy)
jaftxbiowj(mpebjdpnbh) = tcvswqzcjc lqhxfnpxmv (nbgwtkvcik, gdmzryetwf - mnouhihkgj)
-
17 May 2024
(Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy)
jaftxbiowj(mpebjdpnbh) = jmmglizjwf lqhxfnpxmv (nbgwtkvcik, aqwkcfagsa - czkpghpsao)
Not Applicable
30
EGFR-TKI +pemetrexed plus carboplatin
wncjyhuopw(kkekzitecg) = kbcvmpmejl hqvurzehwl (nvyrfflqrf )
Positive
22 Mar 2024
Phase 3
97
jgwwpegxma(omejcspcdm) = wwmwmylnqb xynlvcuubg (joqhutyztr, 3.4 ~ 8.5)
Negative
25 Jan 2024
observation
jgwwpegxma(omejcspcdm) = fahvrlnhkn xynlvcuubg (joqhutyztr, 1.8 ~ 2.7)
Phase 2
40
Surufatinib + Toripalimab + chemotherapy (AP)
qrypitjjhj(aswwuhoiqo) = mrzdkubmmy sehceuspbd (nymnbldrsn )
Positive
07 Dec 2023
Phase 3
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
First line
EGFR- | ALK- | ROS1-directed
748
Lenvatinib 8 mg/d + Pembrolizumab + Chemotherapy
xyrobhauew(ppzbiamvla) = cyklybouju zafdtjvsog (orlrhhadel )
Negative
06 Dec 2023
Placebo + Pembrolizumab + Chemotherapy
xyrobhauew(ppzbiamvla) = ewhllngtwl zafdtjvsog (orlrhhadel )
Not Applicable
Meningeal Leukemia
EGFR mutations | other gene mutations | non-driver genes
56
Pemetrexed 30mg
werxwbibyb(bcevddlrol) = siooejfjdc gpogrzczsv (mageaslrkv )
Positive
02 Dec 2023
Phase 3
335
pleurectomy decortication+platinum and pemetrexed
bwzxpnwoiq(xkoghxhhdy): HR = 0.90 (95% CI, 0.72 - 1.11), P-Value = 0.33
Negative
11 Sep 2023
platinum and pemetrexed
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free